Table 1.
IL-2, IL-12, INF-γ, and IL-10 levels and LST induration (mm) in some patients in the study.
| ID | Day 2 | Day 60 | Treatment outcome | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IL-2 | IL-12 | INF-γ | IL-10 | LST | IL-2 | IL-12 | INF-γ | IL-10 | LST | ||
| 110* | 716 | 00 | 2505 | 16 | 00 | 135 | 4.8 | 438 | 22 | 07 | Not healed |
| 107* | 55 | 2.9 | 2428 | 21 | 03 | 80 | 07 | 865 | 08 | 07 | Healed |
| 104* | 1220 | 4.8 | 2349 | 38 | 03 | 1530 | 18 | 1342 | 47 | 11 | Healed |
| 116* | 00 | 00 | 1016 | 33 | 08 | 34 | 03 | 968 | 81 | 10 | Healed |
| 105* | 150 | 00 | 720 | 00 | 00 | 30 | 18 | 27 | 48 | 06 | Healed |
| 121* | 00 | 08 | 00 | 00 | 00 | 20 | 04 | 531 | 22 | 07 | Healed |
| 123* | 00 | 00 | 101 | 04 | 00 | 00 | 06 | 209 | 09 | 10 | Healed |
| 118* | 00 | 02 | 427 | 12 | 08 | 00 | 4.8 | 85 | 36 | 09 | Healed |
| 129* | 00 | 00 | 342 | 19 | 06 | 15 | 16.5 | 270 | 40 | 11 | Healed |
| 102* | 00 | 1.8 | 74 | 00 | 00 | 42 | 4.8 | 874 | 35 | 07 | Healed |
| 112 | 970 | 06 | 2584 | 345 | 03 | 45 | 00 | 151 | 08 | 08 | Healed |
| 109 | 00 | 3.6 | 2584 | 09 | 00 | 25 | 05 | 626 | 17 | 08 | Healed |
| 108 | 155 | 00 | 2271 | 19 | 00 | 185 | 00 | 1231 | 00 | 05 | Healed |
| 106 | 45 | 4.8 | 2193 | 00 | 00 | 420 | 10.5 | 1342 | 29 | 00 | Healed |
| 103 | 00 | 3.6 | 1732 | 00 | 00 | 52 | 10 | 1342 | 12 | 06 | Healed |
| 101 | 25 | 18 | 1081 | 33 | 00 | 100 | 02 | 1342 | 32 | 00 | Not healed |
| 130 | 00 | 1.2 | 813 | 102 | 04 | 00 | 00 | 14 | 20 | — | Not healed |
| 115 | 00 | 00 | 118 | 113 | 08 | 23 | 18 | 704 | 62 | 12 | Healed |
| 127 | 00 | 6.0 | 00 | 46 | 00 | 00 | 12.9 | 430 | 65 | 07 | Healed |
*Group I patients (SSG + vaccine). IFN-γ, IL-2, Il-12, and IL-10 levels are expressed in pictogram/mL; leishmanin skin test (LST) induration is expressed in mm.